AppliedVR, a leader in digital therapeutics, recently announced a rebranding of its FDA-approved virtual reality therapeutic, RelieVRx, and the results of its three-month durability study.

The new name, AppliedVR, was chosen to better reflect the company's mission to provide evidence-based, patient-centered virtual reality interventions that are delivered by healthcare professionals. The new name also reflects the company's focus on applying virtual reality in clinical settings to improve patient outcomes.

The three-month durability study was conducted to determine the efficacy of RelieVRx over a longer period of time. The study found that the therapeutic was effective in treating chronic pain, anxiety and depression at three-months post-treatment. The findings suggest that the therapeutic is durable and provides long-term relief from symptoms.

AppliedVR also announced the launch of new features for RelieVRx, including a pain scale and breathing exercises. The pain scale allows patients to self-report their pain levels during a session and the breathing exercises help patients learn to manage their pain and distress. The new features are designed to increase the efficacy of the therapeutic and provide a more comprehensive approach to treating chronic conditions.

The rebranding of RelieVRx to AppliedVR and the results of the three-month durability study demonstrate the company's commitment to providing evidence-based, patient-centered virtual reality interventions. The new features and the durability study provide further evidence of the therapeutic's efficacy and demonstrate the potential of virtual reality in treating chronic conditions.

AppliedVR is currently conducting additional research to further investigate the efficacy of RelieVRx and to extend the therapeutic's indications for use. The company is also working to expand its reach to more healthcare providers and patients in order to make virtual reality therapeutics more accessible and affordable.

AppliedVR is committed to providing evidence-based, patient-centered virtual reality interventions that improve patient outcomes. The rebranding of its FDA-approved therapeutic, RelieVRx, and the results of its three-month durability study demonstrate the company's dedication to providing quality care and furthering the use of virtual reality in healthcare.